Archemix Signs Aptamer Therapeutics Agreement with Lilly
Archemix also strengthens IP portfolio through patent license
22-Oct-2008
- USA
“We are excited to enter into this collaboration with a company of the caliber of Lilly to consider pursuing drug targets where aptamer therapeutics may have unique advantages to treat diseases,” said Dr. Errol De Souza, President and Chief Executive Officer of Archemix. “This agreement also supports our strategy to further strengthen Archemix’s position of consolidating all of the significant intellectual property related to aptamer therapeutics.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.